Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

11 Nov 2013

Abstract excerpt

The rapidly growing recognition of the role of oncogenic ROS1 fusion proteins in the malignant transformation of multiple cancers, including lung adenocarcinoma, cholangiocarcinoma, and glioblastoma, is driving efforts to develop effective ROS1 inhibitors for use as molecularly targeted therapy. Using a multidisciplinary approach involving small molecule screening in combination with in vitro and in vivo tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24218589
DOI: 10.1073/pnas.1319583110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteinsPMID 24218589Read ↗

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.Semantic proximity Read ↗

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.Semantic proximity Read ↗

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsSemantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsSemantic proximity Read ↗

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitorsSemantic proximity Read ↗

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.Semantic proximity Read ↗

ROS1 Targeted Therapies: Current Status.Semantic proximity Read ↗

Importance of ROS1 fene fusions in non-small cell lung cancerSemantic proximity Read ↗

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.Semantic proximity Read ↗

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.